Top Markets
Coin of the day
Theradiag S.A. Theradiag S.A.

Theradiag S.A.

ALTER
Rangering i aksjer #31653
Theradiag S.A. specializes in the creation, production, and marketing of... Theradiag S.A. specializes in the creation, production, and marketing of in-vitro diagnostic solutions. Its product line encompasses reagents for autoimmune conditions, IMMUNO-TROL — a comprehensive quality control tool with multiple parameters — and various instruments for testing both autoimmune disorders and infectious diseases. Among its unique offerings are the SQA-V system, engineered for semen analysis, and V-Sperm, a specialized application for digitally uploading and viewing sample results, including pictures and video recordings. The company's advanced instrumentation includes Theralis, which integrates multiplex FIDIS immunofluorescence with ELISA capabilities; Theralis µ, designed as a suitable solution for mid-sized laboratories; and the FIDIS platform, utilized for diverse laboratory analyses. Furthermore, Theradiag provides therapeutic drug monitoring services aimed at managing chronic inflammatory conditions. It also offers LISA tracker, an essential device for overseeing biotherapies, alongside both ELISA and rapid serological tests for SARS-CoV-2. Founded in 1986, Theradiag S.A. is based in Marne La Vallee, France.
Aksjekurs
$1.38
Sist synkronisert: 2023-12-19
Markedsverdi
$12.52M
Endring (1 dag)
0.57%
Endring (1 år)
0.00%
Land
FR
Handel Theradiag S.A. (ALTER)

Kategori

Inntekter for Theradiag S.A. (ALTER)
Inntekter i 2026 TTM: 0
Ifølge Theradiag S.A. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Theradiag S.A. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US